Coherus to launch ranibizumab biosimilar in October
Click Here to Manage Email Alerts
Cimerli, a biosimilar interchangeable with Lucentis, will launch in the United States on Oct. 3, according to a press release from Coherus BioSciences.
The FDA approved Cimerli (ranibizumab-eqrn) in August after meeting standards of biosimilarity and interchangeability to Lucentis (ranibizumab, Genentech). It is indicated for patients with neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularization.
“With the upcoming launch of Cimerli, retina specialists, patients and payers can expect the same efficacy and safety as Lucentis delivered with the comprehensive savings and patient support services that Coherus is known to deliver,” Paul Reider, chief commercial officer of Coherus BioSciences, said in the release. “We look forward to competing in this large and growing market with our dedicated and experienced retina sales team, leveraging our proven commercial expertise as we accelerate adoption of Cimerli over the coming months.”
Cimerli will be available in 0.3 mg and 0.5 mg single-dose vials.
Read more about
Click Here to Manage Email Alerts